Tonix Pharmaceuticals stock halted ahead of FDA approval news
SALT LAKE CITY - SINTX Technologies, Inc. (NASDAQ:SINT), a developer of silicon nitride ceramics for medical devices with a market capitalization of $8.4 million, has completed the acquisition of SiNAPTIC Surgical, LLC, according to a press release issued Friday. The company, which maintains a healthy current ratio of 3.45 and holds more cash than debt, is currently trading near InvestingPro’s Fair Value estimate.
The acquisition brings SiNAPTIC’s portfolio of orthopedic and spine technologies to SINTX, including FDA-cleared interbody spinal implants and foot and ankle fusion wedges, for which a new 510(k) premarket notification was submitted in July 2025.
The company has been implementing a strategic transformation over the past year, divesting non-core assets including the sale of its Maryland-based subsidiary, Technology Assessment & Transfer, Inc. in February 2025. SINTX also shut down its armor ceramics facility in August 2024 and has exited low-margin OEM manufacturing contracts.
As part of the SiNAPTIC acquisition, SINTX has expanded its leadership team with several industry veterans, including Bryan Scheer, M.D., who will serve as Chairman of the Clinical Advisory Board, and Lisa Marie Del Re, who joins as Chief Commercial Officer.
"In just six months, we have rebuilt the Company from the ground up—bringing in world-class leadership, streamlining operations, divesting non-core assets, and executing a focused commercialization strategy," said Eric Olson, Chairman and CEO of SINTX, in the press release.
SINTX continues to provide spinal interbody devices to CTL/Amedica, with over 50,000 devices successfully implanted to date. The company has also filed multiple new patents related to composite implant design, additive manufacturing, and antimicrobial ceramics.
The company’s silicon nitride technology is designed to offer osteoconductive and antimicrobial properties for medical implants. SINTX has been developing and commercializing silicon nitride products that have been implanted in humans since 2008.
In other recent news, SINTX Technologies has announced a definitive agreement to acquire the surgical business assets of SiNAPTIC Holdings, LLC. This acquisition includes intellectual property and product designs for six foot and ankle implant systems, which are backed by clinical development and mechanical testing. The company has also outlined a new strategy to accelerate the commercialization of its silicon nitride technologies following recent leadership changes and a recapitalization. Expanding its focus, SINTX has formed a new subsidiary, SINTX Agribiotech, Inc., to explore agricultural applications of its silicon nitride technology, leveraging its antimicrobial properties for plant protection.
Additionally, SINTX Technologies has reported significant operational progress and financial improvements for the first quarter ending March 31, 2025, as it refocuses on the medical device market. The company plans to develop silicon nitride-based products for healthcare applications, emphasizing biocompatibility and antimicrobial characteristics. In the financial sector, Ascendiant Capital has adjusted its outlook on SINTX Tech shares by reducing the 12-month price target from $30.00 to $28.00 while maintaining a Buy rating. This decision was informed by a net present value analysis, suggesting that there remains significant upside potential. These developments reflect SINTX’s strategic efforts to capitalize on its advanced ceramics technology across multiple sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.